Oracle's AI Backlog Boom Meets Market Skepticism Amid Cash Burn

What happened

Oracle's stock has been cut nearly in half even as its AI backlog explodes, creating a stark contradiction that has forced investors to question whether the market has mispriced the company's potential. The latest master report shows that while demand is undeniably strong, with remaining performance obligations reaching $638 billion, free cash flow remains deeply negative at -$23.7 billion due to heavy capital expenditures. Only about 12% of the backlog is expected to convert to revenue within the next twelve months, and the company plans to raise roughly $40 billion in additional financing, including a $20 billion at-the-market equity offering. This has led to a WAIT rating as the market weighs execution risk against the massive opportunity. The recent article from 24/7 Wall Street highlights that the stock's decline may reflect a rational re-pricing of these risks rather than a market overreaction, but the coming quarters will be decisive in determining whether the backlog translates into profitable growth.

Implication

The stock's sharp decline reflects legitimate concerns about negative free cash flow and heavy financing needs, despite the impressive backlog. While the potential is large, the current valuation still prices in execution that has not yet materialized. The next earnings report and RPO timing disclosures will be critical in determining whether the AI backlog is translating into near-term revenue. Until then, the risk-reward is balanced, and a WAIT stance is appropriate. On the downside, if conversion remains slow or financing plans expand, the stock could fall further toward the $135 attractive entry level; conversely, if Q1 FY2027 shows acceleration and improved prepayments, the stock could rebound toward $185.

Thesis delta

The new article does not introduce any new data or change the fundamental analysis; it merely articulates the market's dilemma. The master report already accounts for the contradiction between backlog growth and cash burn, maintaining a WAIT rating. Therefore, the thesis remains unchanged: Oracle's valuation does not yet offer a sufficient margin of safety, and the stock only becomes attractive on evidence of faster monetization or at a lower price.